Ultragenyx Pharmaceutical Faces Class Action: A Deep Dive into Securities Litigation Trends
Investors in Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE) are facing potential losses as a class action securities lawsuit has been filed, alleging fraud between August 3, 2023, and December 26, 2025. The suit, led by Kahn Swick & Foti, LLC, and spearheaded by former Louisiana Attorney General Charles C. Foti, Jr., highlights a growing trend in securities litigation – swift action following disappointing clinical trial results.
The Core of the Case: Setrusumab’s Failed Trials
The lawsuit centers around Ultragenyx’s setrusumab (UX143), a drug intended for the treatment of Osteogenesis Imperfecta. On December 26, 2025, the company announced that Phase 3 Orbit and Cosmic studies failed to demonstrate a statistically significant reduction in fracture rates. This news triggered a dramatic 42% drop in Ultragenyx’s share price, falling from $34.19 to $19.72 within days. The plaintiffs allege that the company made misleading statements regarding the drug’s efficacy, ultimately harming investors.
Securities Litigation: A Rising Tide
This case isn’t isolated. Securities class action lawsuits are becoming increasingly common, particularly in the biotechnology and pharmaceutical sectors. Disappointing clinical trial data often serves as a catalyst, prompting investors to seek legal recourse. Kahn Swick & Foti, LLC, a firm recognized among the top 10 nationally in settlement value, is actively involved in representing investors in these cases.
Key Dates and Deadlines for Investors
Investors who purchased Ultragenyx stock during the specified period (August 3, 2023 – December 26, 2025) have until April 6, 2026, to apply to the Court to be appointed as lead plaintiff. Although serving as lead plaintiff isn’t required to potentially recover losses, it does offer a more active role in the litigation process. Those seeking more information can contact KSF Managing Partner Lewis Kahn at 1-877-515-1850 or via email at [email protected].
The Role of Boutique Law Firms
Firms like Kahn Swick & Foti, LLC, often described as “boutique” securities litigation firms, are playing an increasingly prominent role in these cases. Their specialized expertise and focus allow them to effectively navigate the complexities of securities law and advocate for investor rights. KSF’s ranking by ISS Securities Class Action Services underscores this trend.
What Does This Mean for Biotech Investors?
This case serves as a reminder of the inherent risks associated with investing in biotechnology companies. Clinical trials are often unpredictable, and negative results can have a significant impact on stock prices. Investors should carefully consider these risks and conduct thorough due diligence before investing in companies reliant on the success of specific drug candidates.
Frequently Asked Questions
- What is a class action lawsuit? A lawsuit brought by one or more people on behalf of a larger group of people who have suffered similar harm.
- What is the deadline to participate in this lawsuit? April 6, 2026, is the deadline to apply to be lead plaintiff.
- Do I have to be the lead plaintiff to recover losses? No, you do not require to be the lead plaintiff to potentially share in any recovery.
- Who is Kahn Swick & Foti, LLC? A securities litigation law firm representing investors.
Pro Tip: Keep detailed records of your investment transactions, including purchase dates, prices, and quantities. This information will be crucial if you decide to participate in the lawsuit.
Did you know? The case is officially titled Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.
For more information about this case, visit https://www.ksfcounsel.com/cases/nasdaqgs-rare/.
